ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • RUNX1 (RUNX Family Transcription Factor 1) • KMT2A (Lysine Methyltransferase 2A) • ETV6 (ETS Variant Transcription Factor 6)

MLL rearrangement

dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • daunorubicin • clofarabine • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)

3ms

VyClo: Vyxeos® With Clofarabine for Pediatric AML (clinicaltrials.gov)

P1, N=25, Recruiting, Princess Maxima Center for Pediatric Oncology

3 months ago

New P1 trial

Vyxeos (cytarabine/daunorubicin liposomal formulation) • clofarabine

3ms

Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia (clinicaltrials.gov)

P2, N=23, Active, not recruiting, Fred Hutchinson Cancer Center | Recruiting --> Active, not recruiting | N=80 --> 23 | Trial completion date: Apr 2027 --> Jul 2026 | Trial primary completion date: Oct 2026 --> Jan 2026

3 months ago

Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date

HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)

clofarabine • fludarabine IV • busulfan • Grafapex (treosulfan)

4ms

NCI-2018-01198: Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia (clinicaltrials.gov)

P2, N=42, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Aug 2026 --> Aug 2027 | Trial primary completion date: Aug 2025 --> Aug 2027

4 months ago

Trial completion date • Trial primary completion date

BCL2 (B-cell CLL/lymphoma 2)

Rituxan (rituximab) • bortezomib • cyclophosphamide • etoposide IV • clofarabine • Arzerra (ofatumumab) • Truxima (rituximab-abbs) • Marqibo (vincristine liposomal) • Hemady (dexamethasone tablets) • Neulasta (pegfilgrastim) • Neupogen (filgrastim)

4ms

Discovery of a novel non-toxic analog of clofarabine for the treatment of triple negative breast cancer. (PubMed, Bioorg Med Chem Lett)

Our preliminary structure-activity relationship study resulted in the identification of analog 9 with enhanced activity against TNBC cells and improved cytotoxicity. One major advantage of analog 9 is that a pilot dose range finding study demonstrated that this analog elicited no signs of toxicity, whereas clofarabine was not well tolerated.

4 months ago

Journal • BRCA Biomarker

BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)

clofarabine

6ms

Cross-Species Functional Genomic Screens Identify Novel Therapeutic Targets in Malignant Peripheral Nerve Sheath Tumors. (PubMed, Am J Pathol)

Five druggable targets were selected for validation, with four of the five agents tested proving effective against human MPNST cells (the POLA1 inhibitor clofarabine, DNTT inhibitor cordycepin, BCL6 inhibitor 79-6 and LPAR1/3 inhibitor Ki16425). Clofarabine was especially effective, potently reducing cell numbers at low nanomolar concentrations and inducing a senescent phenotype, possibly via the p53/p21 pathway. These results demonstrate the utility of cross-species functional oncogenomics for the discovery of novel therapeutic targets relevant to human MPNSTs and suggest that clofarabine warrants further evaluation for its therapeutic potential.

6 months ago

Journal

BCL6 (B-cell CLL/lymphoma 6) • POLA1 (DNA Polymerase Alpha 1)

clofarabine • cordycepin (OVI-123)

6ms

Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children (clinicaltrials.gov)

P2, N=20, Recruiting, West China Second University Hospital

6 months ago

New P2 trial • Real-world evidence

Mekinist (trametinib) • Tafinlar (dabrafenib) • clofarabine

6ms

A Multicenter Clinical Study of Clofarabine as Salvage Therapy in Children with Refractory/Relapsed Langerhans Cell Histiocytosis (ChiCTR2500102536)

P4, N=66, Recruiting, Beijing Children's Hospital, Capital Medical University; Beijing Children's Hospital, Capital Medical University

6 months ago

New P4 trial

clofarabine

6ms

Clofarabine Enhances the Transduction Efficiency of Recombinant AAV2 in the Retina. (PubMed, Invest Ophthalmol Vis Sci)

Clofarabine safely enhances rAAV2 transduction efficiency in both ocular cell models and murine retinas. Its ability to synchronize cell cycles in dividing cells and reprogram transcriptional landscapes in postmitotic cells positions it as a promising adjunct for rAAV-based ocular gene therapy, potentially decreasing therapeutic vector doses and improving clinical outcomes.

6 months ago

Journal

CCNE2 (Cyclin E2)

clofarabine

7ms

Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease (clinicaltrials.gov)

P1/2, N=14, Not yet recruiting, Stanford University

7 months ago

New P1/2 trial

Rituxan (rituximab) • prednisone • clofarabine • melphalan • Kepivance (palifermin)

7ms

Personalized NK Cell Therapy in CBT (clinicaltrials.gov)

P2, N=100, Recruiting, M.D. Anderson Cancer Center | Trial completion date: May 2025 --> May 2027 | Trial primary completion date: May 2025 --> May 2027

7 months ago

Trial completion date • Trial primary completion date

FLT3 (Fms-related tyrosine kinase 3) • BCL2 (B-cell CLL/lymphoma 2)

FLT3 mutation

Rituxan (rituximab) • cyclophosphamide • clofarabine • melphalan • Truxima (rituximab-abbs) • fludarabine IV • busulfan